SCHEMBL4983476

SCHEMBL4983476

Cc1ccc(S(=O)(=O)C(C(N)=O)c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.51
MAPK1 P28482 1/20 0.51
LMNA P02545 3/20 0.49
NPY2R P49146 1/20 0.46
ALDH1A1 P00352 2/20 0.45
SRC P12931 1/20 0.44
HPN P05981 2/20 0.44
PLAU P00749 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
RECQL P46063 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
MMP9 P14780 2/20 0.42
MMP1 P03956 1/20 0.42
MMP13 P45452 1/20 0.42
ADAM17 P78536 1/20 0.42
F2 P00734 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7821908 0.88 SRC (0.55) CYP2D6MAPK1LMNANPY2RALDH1A1
SCHEMBL4798350 0.84 KMT2A (0.44) ALDH1A1RECQLGAAF2PRSS1
SCHEMBL4801052 0.84 ALDH1A1 (0.42) CYP2D6MAPK1LMNAALDH1A1SMN1; SMN2
SCHEMBL7096179 0.84 KMT2A (0.44) LMNAALDH1A1SMN1; SMN2GAAF2
SCHEMBL20550796 0.84 ALDH1A1 (0.47) MAPK1LMNAALDH1A1NPC1MAPT
SCHEMBL4796158 0.82 EGFR (0.45) CYP2D6MAPK1LMNAALDH1A1MAPT
SCHEMBL4464950 0.82 CYP2D6 (0.39) CYP2D6MAPK1LMNANPY2RALDH1A1
SCHEMBL11689700 0.79 NPY2R (0.50) CYP2D6MAPK1LMNANPY2RALDH1A1
SCHEMBL19732918 0.78 LMNA (0.59) CYP2D6MAPK1LMNANPY2RALDH1A1
SCHEMBL5133327 0.77 SRC (0.48) CYP2D6MAPK1LMNAALDH1A1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4307170-A ACID CATALYST - AZO COUPLERS PROMOTE DISCOLORATION AND BLOOM RESISTANCE JAMES RIVER GRAPHICS, INC. (US) 1981-12-22 US claimed
EP-3515895-A1 COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS Vectus Biosystems Limited (AU) 2019-07-31 EP disclosed
WO-2018053588-A1 COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS VECTUS BIOSYSTEMS LIMITED (AU) 2018-03-29 WO disclosed
US-20080114010-A1 Novel Substituted Imidazole Compounds SMITHKLINE BEECHAM CORPORATION 2008-05-15 US disclosed
US-7301021-B2 Substituted imidazole compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-11-27 US disclosed
EP-1014976-B1 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2005-03-02 EP disclosed
EP-0889726-B1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORP (US) 2004-09-15 EP disclosed
EP-0999842-A4 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-08-25 EP disclosed
EP-0935465-B1 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-04-14 EP disclosed
EP-0809499-B1 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORP (US) 2003-11-19 EP disclosed
WO-1997025045-A1 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO disclosed
WO-1997025048-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO disclosed
WO-1997025047-A1 NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO disclosed
WO-1997025046-A1 NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO disclosed
US-5593992-A CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-01-14 US disclosed
US-5593991-A ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR SMITHKLINE BEECHAM CORPORATION 1997-01-14 US disclosed
WO-1996040143-A1 IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-12-19 WO disclosed
WO-1996021452-A1 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORPORATION (US) 1996-07-18 WO disclosed
WO-1996021654-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-07-18 WO disclosed
US-4307170-A ACID CATALYST - AZO COUPLERS PROMOTE DISCOLORATION AND BLOOM RESISTANCE JAMES RIVER GRAPHICS, INC. (US) 1981-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114010-A1 Novel Substituted Imidazole Compounds CREBBP, MAPKAPK2, ATF1 CYP2D6 4679/4885MAPK1 22/4885LMNA 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.